Study of VBC103 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug, VBC103, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink or slow the growth of these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor that has spread or cannot be removed with surgery, and it has gotten worse after or you cannot take standard treatments.
- You must have at least one tumor that can be measured on a scan.
- You must be 18 years or older.
- You must be able to do your daily activities without significant help (ECOG score 0 or 1).
- Your heart function must be normal, with a left ventricular ejection fraction (LVEF) of 50% or more.
- You must have or be willing to provide a sample of your tumor tissue for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called VBC101 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if VBC101 is safe and effective.
This trial tests a new drug called VBC106 in people with advanced solid tumors that have grown despite standard treatments. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called BC2027 for people with advanced solid tumors that have a protein called GPC3. If standard treatments have stopped working, are not available, or caused side effects, this study may offer a new option.
This trial tests an experimental drug called VBC108 in people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and effective.
This trial tests a new experimental drug (called VBC117) for people with advanced solid tumors that have spread. The drug is a type of targeted therapy that seeks out cancer cells and delivers a chemotherapy-like payload directly to them. The study aims to find the best dose and see if it is safe and effective.
This trial tests a new drug called SKB103 for people with advanced solid tumors that have not responded to standard treatments or who cannot tolerate them. The study aims to see if SKB103 is safe and effective.
Hear when a new Participants With Advanced Solid Tumor Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.